(Corrects to remove reference to strong demand in North America in headline and paragraph 1)
HYDERABAD/BENGALURU (Reuters) -Cipla, one of India’s largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday, helped by strong demand.
The company’s consolidated net profit increased nearly 49% to 15.71 billion rupees ($181.6 million) in the October-December quarter, beating analysts’ estimate of 12.12 billion rupees, as per data compiled by LSEG.
Total revenue climbed 7.1% to 70.73 billion rupees, surpassing analysts’ expectations of 69.51 billion rupees.
Invest in Trusted Journalism
Your support helps us deliver unbiased, on-the-ground reporting, in-depth interviews and insightful opinions that matter.
Cipla’s sales are usually lifted by demand for tumour drug Lanerotide, which is its second-biggest revenue generator. However, the company had warned in October that certain supply chain issues related to the drug would last until the fourth quarter.
Last week, rival Dr Reddy’s reported a lower-than-expected quarterly profit due to weak U.S. sales.
Indian generic drugmakers have been struggling with slowing U.S. sales, delayed approvals for new drug applications and lower pricing amid stiff competition, according to analysts.
($1 = 86.5325 Indian rupees)
(Reporting by Rishika Sadam in Hyderabad and Kashish Tandon in Bengaluru; Editing by Eileen Soreng and Mrigank Dhaniwala)
Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibility for its content.
